ALPS Medical Breakthroughs ETF SBIO

Medalist Rating as of | See ALPS Investment Hub

Morningstar’s Analysis SBIO

Will SBIO outperform in the future?

Get our overall rating based on a fundamental assessment of the pillars below.

null Morningstar Automated Analysis

Morningstar Automated Analysis

Summary

ALPS Medical Breakthroughs ETF holds a quantitatively derived Neutral Morningstar Medalist Rating. The rating suggests the model does not express a clear expectation of outperformance or underperformance relative to peers over a full market cycle.

Rated on Published on

Unlock our full analysis with Morningstar Investor

Portfolio Holdings SBIO

  • Current Portfolio Date
  • Equity Holdings —
  • Bond Holdings —
  • Other Holdings —
  • % Assets in Top 10 Holdings 30.2
Top 10 Holdings
% Portfolio Weight
Market Value USD
Sector

CG Oncology Inc

3.94 8M
Healthcare

Travere Therapeutics Inc Ordinary Shares

3.56 7M
Healthcare

Oruka Therapeutics Inc

3.43 7M
Healthcare

Definium Therapeutics Inc Ordinary Shares

3.23 7M
Healthcare

Veradermics Inc

3.10 7M
Healthcare

Dianthus Therapeutics Inc

3.07 6M
Healthcare

Edgewise Therapeutics Inc

2.68 6M
Healthcare

Relay Therapeutics Inc Ordinary Shares

2.53 5M
Healthcare

Amylyx Pharmaceuticals Inc

2.32 5M
Healthcare

IDEAYA Biosciences Inc

2.30 5M
Healthcare

Sponsor Center